Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,347 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioblastoma, Glioma Clear all
Completed Not applicable Interventional Results available

Improving Goals of Care Discussion in Advanced Cancer Patients

NCT02374255
View directory record Official record
Conditions
Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions
GoC intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma

NCT03868943
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Soliramfetol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors

NCT00005955
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

NCT00102648
View directory record Official record
Conditions
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Lonafarnib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Nativis Voyager for Newly Diagnosed GBM

NCT03276286
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nativis Voyager
Device
Lead sponsor
Nativis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

NCT00679354
View directory record Official record
Conditions
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
cilengitide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Oakland, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA

NCT01833273
View directory record Official record
Conditions
Glioblastoma Multiform (Grade IV Astrocytoma)
Interventions
PolyMVA
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00004147
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
incyclinide
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Withdrawn No phase listed Observational

Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors

NCT00897858
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBM
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00305656
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

NCT00879437
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

NCT01435395
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, bevacizumab and bortezomib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

NCT05557292
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
RMC-5552
Drug
Lead sponsor
Nicholas Butowski
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

NCT02431572
View directory record Official record
Conditions
Intracranial Tumors, Glioblastoma, Melanoma
Interventions
PBR PET, Cancer Immunotherapy, Radiation and chemotherapy
Other · Biological · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

NCT00612430
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Etoposide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Drug · Radiation · Device
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00132158
View directory record Official record
Conditions
Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
Interventions
Irinotecan (Camptosar), Gefitinib (Iressa)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Sep 28, 2026, 9:03 PM EDT
Not listed Not applicable Interventional

5-ALA in Recurrent Glioma

NCT02119338
View directory record Official record
Conditions
Glioma
Interventions
5-ala
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

NCT04977375
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 9:03 PM EDT